STOCK TITAN

Logos Global discloses 9.9% Minerva Neurosciences (NERV) ownership stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Minerva Neurosciences, Inc. received a Schedule 13G from Logos Global Management and related entities reporting significant passive ownership of its common stock. Logos Global and several affiliated funds and managers together report beneficial ownership positions up to 4,435,444 shares, or 9.9% of Minerva’s common stock.

The holdings include a mix of common shares and Tranche A warrants for Series A preferred stock that is convertible into additional common shares, subject to a 9.99% voting securities cap that limits conversions above that level. The filing states the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control. Ownership percentages are calculated against 43,274,398 common shares outstanding as of December 23, 2025.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting person consist of (1) 3,311,000 shares of the Issuer's Common Stock, and (2) Tranche A Warrants to acquire 7,000 shares of the Issuer's Series A Preferred Stock that are convertible into 3,311,000 shares of the Issuer's Common Stock. Shares of Series A Preferred Stock may not be converted into shares of Common Stock if that conversion would result in the holder of the shares or any of its affiliates holding more than 9.99% of the Issuer's voting securities. The reporting person's beneficial ownership excludes Tranche B Warrants to acquire 3,500 shares of the Issuer's Series A Preferred Stock because the warrants are not exercisable in the next 60 days. The percentage reported herein is based on 43,274,398 shares of the Issuer's Common Stock outstanding as of December 23, 2025, as reported in the Prospectus filed by the Issuer on January 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting person consist of (1) 3,311,000 shares of the Issuer's Common Stock, and (2) Tranche A Warrants to acquire 7,000 shares of the Issuer's Series A Preferred Stock that are convertible into 3,311,000 shares of the Issuer's Common Stock. Shares of Series A Preferred Stock may not be converted into shares of Common Stock if that conversion would result in the holder of the shares or any of its affiliates holding more than 9.99% of the Issuer's voting securities. The reporting person's beneficial ownership excludes Tranche B Warrants to acquire 3,500 shares of the Issuer's Series A Preferred Stock because the warrants are not exercisable in the next 60 days. The percentage reported herein is based on 43,274,398 shares of the Issuer's Common Stock outstanding as of December 23, 2025, as reported in the Prospectus filed by the Issuer on January 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting person consist of (1) 2,365,000 shares of the Issuer's Common Stock, and (2) Tranche A Warrants to acquire 5,000 shares of the Issuer's Series A Preferred Stock that are convertible into 2,365,000 shares of the Issuer's Common Stock. Shares of Series A Preferred Stock may not be converted into shares of Common Stock if that conversion would result in the holder of the shares or any of its affiliates holding more than 9.99% of the Issuer's voting securities. The reporting person's beneficial ownership excludes Tranche B Warrants to acquire 2,500 shares of the Issuer's Series A Preferred Stock because the warrants are not exercisable in the next 60 days. The percentage reported herein is based on 43,274,398 shares of the Issuer's Common Stock outstanding as of December 23, 2025, as reported in the Prospectus filed by the Issuer on January 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting person consist of (1) 2,365,000 shares of the Issuer's Common Stock, and (2) Tranche A Warrants to acquire 5,000 shares of the Issuer's Series A Preferred Stock that are convertible into 2,365,000 shares of the Issuer's Common Stock. Shares of Series A Preferred Stock may not be converted into shares of Common Stock if that conversion would result in the holder of the shares or any of its affiliates holding more than 9.99% of the Issuer's voting securities. The reporting person's beneficial ownership excludes Tranche B Warrants to acquire 2,500 shares of the Issuer's Series A Preferred Stock because the warrants are not exercisable in the next 60 days. The percentage reported herein is based on 43,274,398 shares of the Issuer's Common Stock outstanding as of December 23, 2025, as reported in the Prospectus filed by the Issuer on January 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting person consist of (1) 3,311,000 shares of the Issuer's Common Stock, and (2) Tranche A Warrants to acquire 7,000 shares of the Issuer's Series A Preferred Stock that are convertible into 3,311,000 shares of the Issuer's Common Stock. Shares of Series A Preferred Stock may not be converted into shares of Common Stock if that conversion would result in the holder of the shares or any of its affiliates holding more than 9.99% of the Issuer's voting securities. The reporting person's beneficial ownership excludes Tranche B Warrants to acquire 3,500 shares of the Issuer's Series A Preferred Stock because the warrants are not exercisable in the next 60 days. The percentage reported herein is based on 43,274,398 shares of the Issuer's Common Stock outstanding as of December 23, 2025, as reported in the Prospectus filed by the Issuer on January 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting person consist of (1) 2,365,000 shares of the Issuer's Common Stock, and (2) Tranche A Warrants to acquire 5,000 shares of the Issuer's Series A Preferred Stock that are convertible into 2,365,000 shares of the Issuer's Common Stock. Shares of Series A Preferred Stock may not be converted into shares of Common Stock if that conversion would result in the holder of the shares or any of its affiliates holding more than 9.99% of the Issuer's voting securities. The reporting person's beneficial ownership excludes Tranche B Warrants to acquire 2,500 shares of the Issuer's Series A Preferred Stock because the warrants are not exercisable in the next 60 days. The percentage reported herein is based on 43,274,398 shares of the Issuer's Common Stock outstanding as of December 23, 2025, as reported in the Prospectus filed by the Issuer on January 6, 2026.


SCHEDULE 13G



Logos Global Management LP
Signature:/s/ Arsani William
Name/Title:Managing Partner
Date:02/17/2026
Logos Global Management GP LLC
Signature:/s/ Arsani William
Name/Title:Managing Member
Date:02/17/2026
Logos Opportunities Fund IV LP
Signature:/s/ Arsani William
Name/Title:Managing Member of Logos Opportunities Fund IV GP LLC, General Partner of Logos Opportunities Fund IV LP
Date:02/17/2026
Logos Opportunities Fund IV GP LLC
Signature:/s/ Arsani William
Name/Title:Managing Member
Date:02/17/2026
William Arsani
Signature:/s/ Arsani William
Name/Title:Reporting person
Date:02/17/2026
Graham G. Walmsley
Signature:/s/ Arsani William
Name/Title:Reporting person
Date:02/17/2026
Exhibit Information

EXHIBIT 99.1 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

Minerva Neurosci

NASDAQ:NERV

NERV Rankings

NERV Latest News

NERV Latest SEC Filings

NERV Stock Data

269.60M
5.44M
Biotechnology
Pharmaceutical Preparations
Link
United States
BURLINGTON